An open label SLV308 [pardoprunox] safety extension to study S308.3.001 in early PD [Parkinson's disease] patients.
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Pardoprunox (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Solvay Pharmaceuticals
- 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 23 Jan 2009 Planned patient numbers amended from 300 to 224 as reported by ClinicalTrials.gov.